$COGT News

If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today

Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today

Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA

Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance

Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?

Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target

FDA Accepts Cogent Biosciences' NDA For Bezuclastinib In Patients With Advanced Systemic Mastocytosis

Cogent Biosciences Enters Commercial Supply Agreement With Hovione On Sept 1, 2026; To Purchase Minimum Percentages Of Bezuclastinib Products From Hovione; Agreement Effective For Five-Year Term With Automatic Two-Year Renewals

$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today

Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat

Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock

Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate